Canfor Announces Closure of Darlington and Estill Sawmills
VANCOUVER, BC, June 26, 2025 /CNW/ – Canfor Corporation (TSX: CFP) announced today its decision to permanently close the Estill and Darlington sawmills in South Carolina, effective August 2025. These closures follow an extended period of persistently weak market conditions and sustained financial losses, which have made continued operations at these facilities no longer viable.
'We understand the significant impact this difficult decision will have on our employees,' said Lee Goodloe, President, Canfor Southern Pine. 'This outcome is in no way a reflection of the dedication and hard work of our teams. We are committed to supporting our employees through this transition, including providing severance payments and exploring opportunities for redeployment within our other operations where possible.'
Approximately 290 employees will be affected by the closures, which will also reduce Canfor's U.S. lumber production capacity by 350 million board feet annually.
Forward-looking statements.Certain statements in this press release constitute 'forward-looking statements' which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Words such as 'expects', 'anticipates', 'projects', 'intends', 'plans', 'will', 'believes', 'seeks', 'estimates', 'should', 'may', 'could', and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and beliefs and actual events or results may differ materially. There are many factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements. Forward-looking statements are based on current expectations and Canfor assumes no obligation to update such information to reflect later events or developments, except as required by law.
About Canfor Corporation.Canfor is a global leader in the manufacturing of high-value low-carbon forest products including dimension and specialty lumber, engineered wood products, pulp and paper, wood pellets and renewable energy. Proudly headquartered in Vancouver, British Columbia, Canfor produces renewable products from sustainably managed forests, at more than 50 facilities across its diversified operating platform in Canada, the United States and Europe. The Company has a 77% stake in Vida AB, Sweden's largest privately owned sawmill company and also owns a 54.8% interest in Canfor Pulp Products Inc. Canfor shares are traded on The Toronto Stock Exchange under the symbol CFP. For more information visit canfor.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Silver Viper Closes $3.5 Million Private Placement
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, June 26, 2025 /CNW/ – Silver Viper Minerals Corp. (the 'Company' or 'Silver Viper') (TSXV: VIPR) (OTC: VIPRF) is pleased to announce that it has closed its $3.5 million non-brokered private placement announced on June 3, 2025 (the 'Offering'), issuing 23,332,792 units of the Company (the 'Units') at a price of $0.15 per Unit for aggregate gross proceeds of $3,490,619. Each Unit consisted of one common share of the Company (each, a 'Share') and one half of one warrant (each, a 'Warrant'). Each Warrant entitles the holder thereof to acquire one Share from the Company at a price of $0.35 per Share for a period of 24 months from the date of issue. All Units issued in connection with the Offering bears a legend indicating that they are subject to a trading restriction for a period of 12 months following the closing of the transaction. The Issuer intends to use the proceeds from the Offering for drilling and other exploration activities at La Virginia and for working capital and other general corporate purposes. As consideration for their services in connection with the Offering, the Finders received a total cash commission of $4,200 and were issued 72,000 Finder's Units (the 'Finder's Units') of the Company. The Finder's Units have the same terms as the Units issued to subscribers in the Offering and bears a legend indicating that they are subject to a trading restriction for a period of 12 months following the closing. Insiders of the Company subscribed for a total of 200,000 Units. Participation by the insiders constitutes a related party transaction as defined under Multilateral Instrument 61-101 ('MI 61-101'). The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the participation in the Private Placement by insiders does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release is not an offer or a solicitation of an offer of securities for sale in the United States, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About the CompanySilver Viper Minerals Corp. is a Canadian-based junior mineral exploration company focused on precious metals exploration in Mexico. The Company is the operator and 100% owner of the La Virginia Gold-Silver Project in Sonora. The Company continues to evaluate and advance mineral exploration opportunities across key mining jurisdictions in Mexico and acquired the Cimarron Project in Sinaloa, Mexico in June 2025. ON BEHALF OF THE BOARD OF DIRECTORS, Steve CopePresident and CEO Follow us on social media:X: @SilverViperCorpLinkedIn: Silver Viper Minerals Silver Viper MineralsYouTube: @SilverViperMinerals Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking InformationThis news release may contain forward-looking statements, including statements with respect to the terms of the Offering, closing of the Offering and use of proceeds of the Offering. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Such factors include, among other things: risks and uncertainties relating to exploration and development, the ability of the Company to obtain additional financing, the need to comply with environmental and governmental regulations, fluctuations in the prices of commodities, operating hazards and risks, competition and other risks and uncertainties, including those described in the Company's financial statements, management discussion and analysis and/or annual information form available on The risk factors identified in such documents are not intended to represent a complete list of factors that could affect the Company. Actual results may differ materially from those currently anticipated in such statements and the Company undertakes no obligation to update such statements, except as required by law.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Canfor Announces Closure of Darlington and Estill Sawmills
VANCOUVER, BC, June 26, 2025 /CNW/ – Canfor Corporation (TSX: CFP) announced today its decision to permanently close the Estill and Darlington sawmills in South Carolina, effective August 2025. These closures follow an extended period of persistently weak market conditions and sustained financial losses, which have made continued operations at these facilities no longer viable. 'We understand the significant impact this difficult decision will have on our employees,' said Lee Goodloe, President, Canfor Southern Pine. 'This outcome is in no way a reflection of the dedication and hard work of our teams. We are committed to supporting our employees through this transition, including providing severance payments and exploring opportunities for redeployment within our other operations where possible.' Approximately 290 employees will be affected by the closures, which will also reduce Canfor's U.S. lumber production capacity by 350 million board feet annually. Forward-looking statements in this press release constitute 'forward-looking statements' which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Words such as 'expects', 'anticipates', 'projects', 'intends', 'plans', 'will', 'believes', 'seeks', 'estimates', 'should', 'may', 'could', and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and beliefs and actual events or results may differ materially. There are many factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements. Forward-looking statements are based on current expectations and Canfor assumes no obligation to update such information to reflect later events or developments, except as required by law. About Canfor is a global leader in the manufacturing of high-value low-carbon forest products including dimension and specialty lumber, engineered wood products, pulp and paper, wood pellets and renewable energy. Proudly headquartered in Vancouver, British Columbia, Canfor produces renewable products from sustainably managed forests, at more than 50 facilities across its diversified operating platform in Canada, the United States and Europe. The Company has a 77% stake in Vida AB, Sweden's largest privately owned sawmill company and also owns a 54.8% interest in Canfor Pulp Products Inc. Canfor shares are traded on The Toronto Stock Exchange under the symbol CFP. For more information visit
Malaysian Reserve
10 hours ago
- Malaysian Reserve
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ — USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns around drug affordability and access. These headwinds are forcing a shift in expectations — placing the burden of innovation on the private sector, where companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Citius Oncology, Inc. (NASDAQ: CTOR), ADC Therapeutics SA (NYSE: ADCT), and OS Therapies Incorporated (NYSE-American: OSTX). The shift reflects more than a funding gap — it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble biotech firms are advancing targeted treatments, combination trials, and regulatory conversations once dominated by legacy institutions. Against this backdrop, market watchers see a pivotal window opening for investors willing to back the next wave of oncology innovation. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress. Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications. 'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients,' said Jared Kelly, CEO of Oncolytics Biotech. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders.' Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers. Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential. Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations. In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation. Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs. 'Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date,' said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. 'We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors.' Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development. As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction. Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has entered into a strategic partnership with Fosun Pharma to accelerate development of TEV-56278, a novel anti-PD1-IL2 immunotherapy designed using its proprietary ATTENUKINE™ technology. 'This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring acceleration of our pipeline,' said Eric Hughes, MD, PhD, Executive Vice President, Teva Global R&D and Chief Medical Officer. 'TEV-56278 demonstrates the strength of Teva's innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients.' This investigational fusion protein is aimed at selectively delivering IL-2 to PD-1+ T cells, potentially enhancing anti-tumor response while limiting toxic side effects. Under the agreement, Fosun will lead clinical, manufacturing, and commercial activity in China and parts of Southeast Asia, while Teva retains global rights elsewhere. Citius Oncology, Inc. (NASDAQ: CTOR) recently announced that it expects to commercially launch LYMPHIR™ in 2025 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), pending FDA approval. 'We've made steady and meaningful progress toward commercialization over the past several months,' said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. 'With our supply chain secured, market access supported, and no anticipated impediments to reimbursement, we are encouraged by the momentum we've built. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community.' ADC Therapeutics SA (NYSE: ADCT) recently reported updated Phase 2 data from an investigator-initiated trial of ZYNLONTA® in relapsed/refractory marginal zone lymphoma (r/r MZL), showing an 84.6% overall response rate and a 69.2% complete response rate. 'Based on the updated Phase 2 IIT data to be shared at ICML, we are encouraged by the potential opportunity in r/r MZL and look forward to seeing additional data, as the trial expands to other sites.' said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. 'As this trial progresses, assuming the results continue to be positive, we plan to potentially pursue a regulatory pathway and compendia in parallel as soon as sufficient data are available.' The trial also showed encouraging durability, with complete responses maintained in 17 of the 18 patients who achieved a complete response and progression-free survival of 92.9% at 12 months. ZYNLONTA was generally well tolerated, with safety findings consistent with its existing clinical profile. OS Therapies Incorporated (NYSE-American: OSTX) received positive written feedback from the FDA following a Type D meeting regarding its lead candidate, OST-HER2, for pediatric lung metastatic osteosarcoma. 'We are pleased with the feedback we received from the FDA regarding the use of external control comparators in settings where placebo-controlled randomization trials are not feasible – particularly in rare pediatric diseases such as the indication treated by OST-HER2 ,' said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. 'Moreover, we received additional collaborative input regarding suggested statistical methods as we seek to compare OST-HER2 active treatment with external control arm(s) to support a Biologics Licensing Application (BLA) via the Accelerated Approval Program. Taken together, the feedback gives us insight on the FDA's current position and allows us to be fully prepared for the End of Phase 2 Meeting.' The agency supported the company's proposed use of external comparators in its Phase 2b trial, potentially laying groundwork for accelerated approval. OS Therapies has submitted requests for an End of Phase 2 Meeting and Breakthrough Therapy Designation, with regulatory filings expected to advance in late 2025. Source: CONTACT:USA NEWS GROUPinfo@ 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Video – – View original content:
